Indivior Pharmaceuticals Financials - Benzinga

Indivior Pharmaceuticals Inc

INDVNASDAQ

Trade with Public

Trade with Public

$34.28

-0.19-0.55%

Last update: Sep 15, 10:26 AM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Indivior Pharmaceuticals Financials

Indivior Pharmaceuticals (INDV) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Indivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.215B-$1.285B to $1.295B-$1.365B vs $1.245B Est

Indivior Pharmaceuticals (NASDAQ:INDV) raises FY2026 sales outlook from $1.215 billion-$1.285 billion to $1.295 billion-$1.365 billion vs $1.245 billion estimate.

Benzinga Newsdesk

PRO
Indivior Q2 Adj. EPS $1.15 Beats $0.87 Estimate, Sales $343.000M Beat $307.550M Estimate

Benzinga Newsdesk

Earnings Scheduled For April 30, 2026

Benzinga Insights

PRO
Indivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.125B-$1.195B to $1.215B-$1.285B vs $1.156B Est

Indivior Pharmaceuticals (NASDAQ:INDV) raises FY2026 sales outlook from $1.125 billion-$1.195 billion to $1.215 billion-$1.285 billion vs $1.156 billion estimate.

Benzinga Newsdesk

PRO
Indivior Q1 Adj. EPS $0.96 Beats $0.66 Estimate, Sales $317.000M Beat $272.840M Estimate

Indivior (NASDAQ:INDV) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.66 by 45.45 percent. This is a 134.15 percent increase over earnings of $0.41 per share from the same

Benzinga Newsdesk

Insights into Indivior Pharmaceuticals Q4 Earnings

Benzinga Insights